In vivo gastric detection of α-synuclein inclusions in Parkinson's disease

Movement Disorders

Volumn 30, Issue 4, 2015, Pages 517-524

  Sánchez Ferro, Álvaro ^a,b,c,d   Rábano, Alberto ^e   Catalán, María José ^b   Rodríguez Valcárcel, Fernando Canga ^a   Díez, Servando Fernández ^b   Herreros Rodríguez, Jaime ^a,b   García Cobos, Elvira ^f   Álvarez Santullano, Marina Mata ^f   López Manzanares, Lydia ^f,g   Mosqueira, Antonio J ^g   Desojo, Lydia Vela ^h   López Lozano, Juan José ^f   López Valdés, Eva ^b   Sánchez Sánchez, Rafael ⁱ   Molina Arjona, José Antonio ^a,b,d  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^e Instituto de Salud Carlos III   (Spain)

^f HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^g HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^h HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

ⁱ HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Autonomic nervous system; Biological markers; Lewy bodies; Parkinsonian disorders; Pathology; Prodromal stage

Indexed keywords

ALPHA SYNUCLEIN; CARBIDOPA; LEVODOPA;

ABDOMINAL PAIN; AGE DISTRIBUTION; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASYMPTOMATIC DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENDOSCOPIC BIOPSY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTESTINE INNERVATION; MALE; NEUROPATHOLOGY; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SEX ALLOCATION; STOMACH BIOPSY; STOMACH MUCOSA; TREATMENT INDICATION;

EID: 84964277355     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25988     Document Type: Article

References (41)

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
2. Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013;136:2419-2431.
3. Gasser T. Genomic and proteomic biomarkers for Parkinson disease. Neurology 2009;72(Suppl):S27-S32.
4. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-840.
5. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
6. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of α-synuclein in neurological disorders. Lancet Neurol 2011;10:1015-1025.
7. Derkinderen P, Rouaud T, Lebouvier T, et al. Parkinson disease: the enteric nervous system spills its guts. Neurology 2011;77:1761-1767.
8. Lebouvier T, Neunlist M, Bruley des Varannes S, et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One 2010;5:e1278, doi: 10.1371/journal.pone.0012728.
9. Shannon KM, Keshavarzian A, Mutlu E, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord 2012;27:709-715.
10. Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord 2012;27:716-719.
11. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006;396:67-72.
12. Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol 2009;201:1-119.
13. Cersosimo MG, Raina GB, Pecci C, et al. Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms. J Neurol 2012, doi:10.1007/s00415-012-6801-2.
14. Gelpi E, Navarro-Olano J, Tolosa E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 2014 Jan 2. doi:10.1002/mds.25776.
15. Pouclet H, Lebouvier T, Coron E, Neunlist M, Derkinderen P. Lewy pathology in gastric and duodenal biopsies in Parkinson's Disease. Mov Disord 2012;27:708, doi: 10.1002/mds.24993.
16. Pan-Montojo F, Anichtchik O, Dening Y, et al. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLos One 2010;5:e8762, doi: 10.1371/journal.pone.0008762.
17. Pan-Montojo F, Schwarz M, Winkler C, et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2012;2:989, doi: 10.1038/srep00898.
18. Kelly LP, Carvey PM, Keshavarzian A, et al. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov Disord 2013 Nov 4.
19. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-223.
20. Lang AE. A critical appraisal of the premotor symptoms of Parkinson's disease: potential usefulness in early diagnosis and design of neuroprotective trials. Mov Disord 2011;26:775-783.
21. Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 2012;72:893-901.
22. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale (UPDRS). In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Developments in Parkinson's Disease. Vol 2. Florham Park, NJ: Macmillan Health Care Information; 1987, pp 153-164.
23. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
24. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990;40:1529-1534.
25. Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 2007;22:1901-1911.
26. Parkinson J. An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci 2002;14:223-236.
27. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-870. doi:10.1093/brain/awf080.
28. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: a prospective study. Can J Neurol Sci 1991;18:275-278.
29. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57:1497-1499.
30. Cersósimo MG, Perandones C, Micheli FE, et al. Alpha-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson's disease patients. Mov Disord 2011;26:188-190.
31. Michell AW, Luheshi LM, Barker RA. Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease. Neurosci Lett 2005;381:294-298.
32. van Duinen SG, Lammers GJ, Maat-Schieman ML, Roos RA. Numerous and widespread alpha-synuclein-negative Lewy bodies in an asymptomatic patient. Acta Neuropathol 1999;97:533-539.
33. Del Tredici K, Braak H. Lewy pathology and neurodegeneration in premotor Parkison's disease. Mov Disord 2012;27:597-607. doi:10.1002/mds.24921.
34. Visanji NP, Marras C, Hazrati LN, Liu LWC, Lang AE. Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord 2013; doi:10.1002/mds.25789.
35. Gray MT, Munoz DG, Gray DA, et al. α-Synuclein in the appendiceal mucosa of neurologically intact subjects. Mov Disord. 2013 Dec 18. doi: 10.1002/mds.25779.
36. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174.
37. Lebouvier T, Neunlist M, Bruley des Varannes S, et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One 2010;5:e12728, doi: 10.1371/journal.pone.0012728.
38. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F, et al. Do alpha-synuclein aggregates in autonomic plexuses predate Lewis bodies disorders?: a cohort study. Neurology 2007;68:2012-2018.
39. Sunwoo MK, Hong JY, Choi J, et al. α-Synuclein pathology is related to postoperative delirium in patients undergoing gastrectomy. Neurology 2013;80:810-813. doi:10.1212/WNL.0b013e3182840782.
40. Croisier E, MRes DE, Deprez M, et al. Comparative study of commercially available anti-alpha-synuclein antibodies. Neuropathol Appl Neurobiol 2006;32:351-356.
41. Kovacs GG1, Wagner U, Dumont B, et al. An antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology. Acta Neuropathol 2012;124:37-50. doi:10.1007/s00401-012-0964-x.